A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects The objective of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe Rheumatoid Arthritis (RA) subjects.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate The objective of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe Rheumatoid Arthritis (RA) subjects who are Methotrexate-Inadequate Responders (MTX-IR).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer To determine the PFS of MDV3100 as compared to bicalutamide

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin’s Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant To determine objective response rate (ORR) (complete remission [CR] + partial remission [PR]) per [the International Working Group (IWG) Revised Response Criteria for Malignant Lymphomas (2007)].

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects with Moderate to Severe Psoriasis To establish the safety of alefacept when administered to adolescent subjects with moderate to severe psoriasis

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multinational study, Phase 3, Randomized, Double-blind, and controlled against a Placebo that studies the Efficacy and the Safety of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by radiographic progression-free survival (rPFS) based on central review

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy Determine the efficacy superiority of ASP2215 and/or ASP2215 plus azacitidine versus azacitidine as measured by overall survival (OS).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Effectiveness and safety of gilteritinib (ASP2215) as maintenance treatment (maintain the response achieved during the first course of treatment) for Acute myeloid leukemia patients who are in a first complete remission (no residual leukemia cells in your bone marrow), with mutations in the FLT3 gene compared to placebo given alone. Fenntartó kezelésként alkalmazott gilteritinib (ASP2215) hatásosságának és biztonságosságának vizsgálata első teljes remisszió időszakában levő (tumorsejt nem található a csontvelőben), FLT3 génmutációval rendelkező, akut myeloid leukémiában szenvedő betegek körében, placebóhoz viszonyítva The primary objective is to compare relapse-free survival (RFS) between subjects with FLT3/ITD AML in first complete remission (CR1) without transplant and who are randomized to receive gilteritinib o...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects with Stage III (Unresectable) or Stage IV Melanoma To evaluate 6-month Progression Free Survival (PFS).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 3b Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in Patients with Recent Onset Symptomatic Atrial Fibrillation The primary safety objective of this study is to evaluate the safety of vernakalant injection in subjects with recent onset (AF > 3 hours to less than or equal to 7 days), symptomatic atrial fibrillat...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune